FOLH1 and renal cell carcinoma: Some recent reports have shown that PSMA-PET may potentially be more sensitive than FDG-PET in metastatic RCC, emerging as a new imaging tool in patients with oligometastatic disease receiving definitive local therapies [40,54,55].